BAYN - Bayer Aktiengesellschaft
XETRA
->
Healthcare
->
Drug Manufacturers—General
Leverkusen,
Germany
Type: Equity
BAYN price evolution
BAYN
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $13830 | $17031 | $17794 | $12815 |
| Inventory | $12945 | $13088 | $13437 | $13947 |
| Total current assets | $33131 | $40144 | $40167 | $37556 |
| Long term investments | ||||
| Property, plant & equipment | $13178 | $13487 | $13472 | $13321 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $106946 | $119859 | $119881 | $116259 |
| Current liabilities | ||||
| Accounts payable | $6561 | $6127 | $6398 | $7456 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $25048 | $31561 | $30630 | $29457 |
| Long term debt | $36672 | $37397 | $37987 | $38176 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $76387 | $84172 | $84276 | $83332 |
| Shareholders' equity | ||||
| Retained earnings | $28044 | $14911 | $14829 | $12151 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4564 | $4191 | ||
| Short term investments | $669 | $1311 | ||
| Net receivables | $12522 | $13450 | $12980 | $12143 |
| Inventory | $13947 | $13636 | $11314 | $10961 |
| Total current assets | $37556 | $37760 | $32578 | $35660 |
| Long term investments | $2612 | $1998 | ||
| Property, plant & equipment | $13321 | $13674 | $12688 | $11710 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $116259 | $124877 | $120241 | $117046 |
| Current liabilities | ||||
| Accounts payable | $7456 | $7545 | $6792 | $5683 |
| Deferred revenue | ||||
| Short long term debt | $4155 | $8358 | ||
| Total current liabilities | $29457 | $35084 | $29403 | $36728 |
| Long term debt | $38170 | $33781 | $35552 | $32271 |
| Total noncurrent liabilities | $33193 | |||
| Total debt | ||||
| Total liabilities | $83332 | $86104 | $87073 | $86347 |
| Shareholders' equity | ||||
| Retained earnings | $12175 | $17233 | $13345 | $13057 |
| Other shareholder equity | -$105 | $652 | $17160 | $14952 |
| Total shareholder equity | $33020 | $30524 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $13765 | $11862 | ||
| Cost of revenue | ||||
| Gross Profit | $8302 | $7376 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $5210 | $5187 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $589 | $302 | ||
| Interest expense | -$501 | -$545 | ||
| Net income | ||||
| Net income | $2000 | $1337 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $47637 | $50739 | $41400 | |
| Cost of revenue | $15727 | |||
| Gross Profit | $27888 | $30868 | $25673 | |
| Operating activities | ||||
| Research & development | $4884 | |||
| Selling, general & administrative | $13886 | |||
| Total operating expenses | $19465 | $22889 | $34525 | |
| Operating income | $6875 | |||
| Income from continuing operations | ||||
| EBIT | $6875 | |||
| Income tax expense | $1321 | $504 | -$1689 | |
| Interest expense | -$852 | -$2708 | -$1500 | |
| Net income | ||||
| Net income | -$2941 | $4150 | -$10495 | |
| Income (for common shares) | -$10495 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $1458 | -$2300 | $303 | -$3517 |
| Financing activities | ||||
| Dividends paid | -$118 | -$113 | -$2379 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$5069 | -$15 | $677 | -$679 |
| Effect of exchange rate | -$48 | $36 | -$12 | -$185 |
| Change in cash and equivalents | -$1288 | -$2019 | -$1182 | $736 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $1000 | -$10495 | ||
| Operating activities | ||||
| Depreciation | $1609 | $3444 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $5089 | $4903 | ||
| Investing activities | ||||
| Capital expenditures | -$2611 | -$2418 | ||
| Investments | $4302 | -$4027 | ||
| Total cash flows from investing | -$3517 | -$2381 | $855 | -$4073 |
| Financing activities | ||||
| Dividends paid | -$2379 | -$1985 | -$1993 | -$2751 |
| Sale and purchase of stock | ||||
| Net borrowings | -$2452 | $4467 | ||
| Total cash flows from financing | -$679 | -$4220 | -$5645 | $423 |
| Effect of exchange rate | -$185 | $112 | $35 | -$240 |
| Change in cash and equivalents | $736 | $607 | $373 | $1006 |
News
Fundamentals
| Market cap | $26.87B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 982.42M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.32 |
| Quick ratio | 0.81 |